At the 2025 BIO Asia–Taiwan Innovation Forum S3, top experts from Chugai, Novartis, GSK, and CMIC shared how Taiwan can ride the wave of global pharma innovation — from antibodies to radioligand therapy and regenerative medicine!

Key Highlights:
Chugai: 5 cutting-edge platforms (antibodies, mid-size molecules & more) drive 21% revenue growth
Novartis: Radioligand therapy (RLT) targets multiple cancers—ushering in a new era of precision oncology
GSK: Vaccination is health investment—$1 USD spent yields $3.4 USD in health return
CMIC: 3 must-know tips to enter Japan's booming regenerative medicine market

Taiwan is poised to benefit as part of this next-gen global innovation value chain!

Dive deeper: https://reurl.cc/WOrV2y

#Globalbio #BIOAsiaTaiwan #DrugInnovation #RadioligandTherapy #Vaccines #RegenerativeMedicine #PharmaStrategy #BiotechAsia #TaiwanBiotech